Bourlière, M., Bronowicki, J., de Ledinghen, V., Hézode, C., Zoulim, F., Mathurin, P., Tran, A., Larrey, D. G., Ratziu, V., Alric, L., Hyland, R. H., Jiang, D., Doehle, B., Pang, P. S., Symonds, W. T., Subramanian, G. M., McHutchison, J. G., Marcellin, P., Habersetzer, F., Guyader, D., Grangé, J., Loustaud-Ratti, V., Serfaty, L., Metivier, S., Leroy, V., Abergel, A., & Pol, S. (n.d.). ledipasvir-sofosbuvir with or without ribavirin to treat patients with HCV genotype 1 infection and cirrhosis non-responsive to previous protease-inhibitor therapy: a randomised, double-blind, phase 2 trial (SIRIUS). Lancet infectious diseases, 15(4), 397–404. http://access.bl.uk/ark:/81055/vdc_100051427177.0x000013